Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Lytenava 25 mg/mL solution for injection {equilateral_black_triangle}

Active Ingredient:
Bevacizumab gamma
Company:  
Outlook Therapeutics Ltd See contact details
ATC code: 
S01LA08
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Guide to Lytenava (bevacizumab gamma) 25 mg/mL solution for injection

This guide is provided by Outlook Therapeutics for adult patients who have been prescribed LYTENAVA™ treatment for neovascular (wet) AMD.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Outlook Therapeutics Ltd
Company image
Address
Leavesden Park Suite 1, 5 Hercules Way, Watford, Hertfordshire, WD25 7GS, UK
Telephone
+44 (0)20 3872 3526
Medical Information Direct Line
+44 (0)20 3872 3526
Medical Information e-mail
[email protected]